Last $58.35 USD
Change Today -0.05 / -0.09%
Volume 1.9M
DGX On Other Exchanges
New York
As of 8:04 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/11/13 - $64.10
52 Week Low
02/7/14 - $50.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. It offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; and risk assessment services for the life insurance industry. The company also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, it provides molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the brand names of Atria and AlleleSeqr. Further, the company offers Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, including vital signs and progress notes; and ChartMaxx, an electronic document management system for hospitals. The company offers its diagnostic information services to patients, physicians, hospitals, integrated delivery networks, health plans, employers, and others through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

41,000 Employees
Last Reported Date: 02/18/14
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $472.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $573.9K
Senior Vice President of Clinical Franchises
Total Annual Compensation: $520.0K
Senior Vice President and General Counsel
Total Annual Compensation: $492.1K
Compensation as of Fiscal Year 2013.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Inc. Proposes Amending the Certificate of Incorporation

Quest Diagnostics Inc. proposed amending the company's Certificate of Incorporation to remove supermajority voting requirements and to permit stockholders to cause the company to call special meetings.

Focus Diagnostics Receives FDA Clearance for Moderate Complexity Simplexa HSV 1 & 2 Direct Molecular Test for Aiding the Diagnosis of Encephalitis

Quest Diagnostics announced that its Focus Diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler. The test, which is now available for purchase in the United States, is the first molecular test to be cleared by the FDA for the qualitative detection and differentiation of herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) in cerebrospinal fluid (CSF) from patients suspected of HSV central nervous system (CNS) infection, including encephalitis. The test uses a proprietary process that eliminates nucleic acid extraction, so clinicians can expect results within about an hour after providing a specimen for testing. Encephalitis is an inflammation of the brain often caused by the herpes simplex or other viruses. The Infectious Diseases Society of America (IDSA) recommends herpes simplex PCR testing on all CSF specimens in patients with encephalitis. HSV encephalitis occurs in all ages and during all seasons, with HSV-1 encephalitis more common in adults and HSV-2 encephalitis more common in newborn infants. Accurate determination of the virus causing encephalitis can influence treatment decisions and outcomes. The moderate complexity categorization of the Simplexa HSV 1 & 2 Direct molecular test significantly broadens the potential clinical access to the technology. Moderate complexity laboratories, defined by the Clinical Laboratory Improvement Amendments (CLIA), include certain types of physician's offices, community hospitals, health clinics and integrated delivery networks. These facilities typically lack the personnel and technology to perform high complexity molecular diagnostic tests. Since the test can be performed in these moderate complexity labs, patient results may be obtained readily to help speed therapeutic decisions.

Quest Diagnostics Inc. Issues $300,000,000 Aggregate Principal Amount of 2.700% Senior Notes Due 2019 and $300,000,000 Aggregate Principal Amount of 4.250% Senior Notes Due 2024

On March 17, 2014, Quest Diagnostics Incorporated issued $300,000,000 aggregate principal amount of 2.700% Senior Notes due 2019 and $300,000,000 aggregate principal amount of 4.250% Senior Notes due 2024. The company will pay interest on the 2019 Notes and the 2024 Notes on April 1 and October 1 of each year, beginning on October 1, 2014. The 2019 Notes will mature on April 1, 2019. The 2024 Notes will mature on April 1, 2024. The Notes will be the senior unsecured obligations of the company and will rank equally with the company’s other and future senior unsecured obligations. The Notes will not be entitled to the benefit of any sinking fund. The Notes were issued pursuant to an indenture dated as of June 27, 2001 among the Company, the guarantors (as defined therein) and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented by the first through fifteenth supplemental indentures of various dates, among the Company, the Trustee and the subsidiary guarantors party thereto and as further supplemented by a sixteenth supplemental indenture dated March 17, 2014 between the Company and the Trustee (collectively, the “Indenture”). The Indenture contains covenants that, among other things, will limit the ability of the company and any subsidiary guarantors to create certain liens; enter into certain sale and leaseback transactions; consolidate, merge or transfer all or substantially all of the Company’s assets and the assets of the company’s subsidiaries on a consolidated basis; incur indebtedness of non-guarantor subsidiaries; and make restricted payments to certain non-guarantor subsidiaries. The Indenture provides for customary events of default. Upon a change of control triggering event (as defined in the Indenture), the company will be required to make an offer to purchase the Notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to the date of repurchase.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $58.35 USD -0.05

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $95.11 USD +0.42
Hologic Inc $20.48 USD -0.25
Laboratory Corp of America Holdings $99.85 USD -0.53
Myriad Genetics Inc $39.68 USD +0.28
QIAGEN NV €15.18 EUR -0.152
View Industry Companies

Industry Analysis


Industry Average

Valuation DGX Industry Range
Price/Earnings 11.0x
Price/Sales 1.2x
Price/Book 2.1x
Price/Cash Flow 9.1x
TEV/Sales 0.7x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at